Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 5, Issue 1, 2011, Pages 45-49

  Bocci, Velio ^a   Zanardi, Iacopo ^a   Huijberts, Maya S P ^b   Travagli, Valter ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced glycation end products; Antioxidants; Heme oxygenase I; Oxidative stress; Oxygen ozonetherapy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIBIOTIC AGENT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; GROWTH FACTOR; INSULIN; ORAL ANTIDIABETIC AGENT; REACTIVE OXYGEN METABOLITE;

AMADORI REARRANGEMENT; ANTIBIOTIC THERAPY; DIABETES MELLITUS; DIABETIC FOOT; GLYCATION; HUMAN; HYPERGLYCEMIA; LIFESTYLE MODIFICATION; MAGGOT THERAPY; NONHUMAN; OXIDATIVE STRESS; OZONE THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; VACUUM ASSISTED CLOSURE;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; OXIDATIVE STRESS; OXYGEN INHALATION THERAPY; OZONE;

EID: 79955951796     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2010.05.014     Document Type: Review

References (70)

1. Rocchini AP. Childhood obesity and a diabetes epidemic. N Engl J Med 2002;346:854-5. (Pubitemid 34984661)
2. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001;17:189-212. (Pubitemid 32624602)
3. Diabetes Prevention Program Research Group.. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
4. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31:S12-54.
5. Inzucchi SE. Oral antihyperglycemic therapy for Type 2 diabetes: scientific review. JAMA 2002;287:360-72. (Pubitemid 34256388)
6. Holmboe ES. Oral antihyperglycemic therapy for Type 2 diabetes, clinical application. JAMA 2002;287:373-6. (Pubitemid 34251970)
7. Pickup J, Mattock M, Kery S. Glycaemic control with continuous subcutaneous insulin infusion comparedwithintensive insulin injections in patients with Type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:1-6.
8. Resnick HE, Howard BV. Diabetes and cardiovascular disease. Annu Rev Med 2002;53:245-67. (Pubitemid 34177881)
9. Navarro JF, MIlena FJ, Mora C, Leon C, Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin- converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 2006;26:562-70. (Pubitemid 46143878)
10. Boulton AJ. The pathogenesis of diabetic foot problems: an overview. Diabet Med 1996;13:S12-6.
11. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 2003;111:431-3. (Pubitemid 36227996)
12. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-50. (Pubitemid 34546899)
13. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319-36. (Pubitemid 34177884)
14. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-43. (Pubitemid 34087557)
15. Cameron NE, Cotter MA. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994;10:189-224. (Pubitemid 24306134)
16. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20. (Pubitemid 34000785)
17. Brownlee M. A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest 2003;112:1788-90. (Pubitemid 38063700)
18. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-12.
19. West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000;17:171-80. (Pubitemid 30212288)
20. Parks DA, Granger DN. Ischaemia-induced vascular changes: role of xanthine oxidase and hydroxyl radicals. Am J Physiol 1983;245:G285-9.
21. Houston , Estevez A, Chumley P, Aslan M, MarklundS S, Parks DA, et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem 1999;274:4985-94.
22. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A 2001;98:15215-20. (Pubitemid 34013994)
23. Mallozzi C, Di Stasi AM, Minetti M. Peroxynitrite modulates tyrosine-dependent signal transduction pathway of human erythrocyte band 3. FASEB J 1997;11:1281-90.
24. Zoukourian C, Wautier MP, Chappey O, Dosquet C, Rohban T, Schmidt AM, et al. Endothelial cell dysfunction secondary to the adhesion of diabetic erythrocytes. Modulation by iloprost. Int Angiol 1996;15:195-200. (Pubitemid 26413835)
25. Rattan V, Shen Y, Sultana C, Kumar D, Kalra VK. Diabetic RBC-induced oxidant stress leads to transendothelial migration of monocyte-like HL-60 cells. Am J Physiol 1997;273:E369-75.
26. van Sloten TT, Friederichs SA, Huijberts MS, Schaper NC. Diabetic foot: new insights into pathophysiology and treatment. Ned Tijdschr Geneeskd 2008;152:2400-5.
27. Packer L, Witt EH, Tritschler HJ. α-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995;19:227-50.
28. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, et al. Vitamin C pharmacokinetics in health volunteers: evidence for a recommended dietary allowance. Proc Nat Acad Sci U S A 1996;93:3704-9. (Pubitemid 26125678)
29. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-8. (Pubitemid 26021690)
30. Halliwell B. Vitamin C: poison, prophylactic or panacea? Trends Biochem Sci 1999;24:255-9.
31. McCall MR, Frei B. Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic Biol Med 1999;26:1034-53.
32. Polidori MC, Stahl W, Eichler O, Niestroj I, Sies H. Profiles of antioxidants in human plasma. Free Radic Biol Med 2001;30:456-62. (Pubitemid 32162953)
33. Victor VM, McCreath KJ, Rocha M. Recent progress in pharmacological research of antioxidants in pathological conditions: cardiovascular health. Recent Pat Antiinfect Drug Discov 2006;1:17-31.
34. Traverso N, Menini S, Odetti P, Pronzato MA, Cottalasso D, Marinari UM. Diabetes impairs the enzymatic disposal of 4-hydroxynonenal in rat liver. Free Radic Biol Med 2002;32:350-9. (Pubitemid 34159089)
35. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61. (Pubitemid 27121266)
36. Huijberts MS, Wolffenbuttel BH, Boudier HA, Crijns FR, Kruseman AC, Poitevin P, et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993;92:1407-11. (Pubitemid 23273918)
37. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 1996;50:627-34. (Pubitemid 26274394)
38. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998;95:4630-4.
39. Youssef S, Nguyen DT, Soulis T, Panagiotopoulos S, Jerums G, Cooper ME. Effect of diabetes and aminoguanidine therapy on renal advanced glycation endproduct binding. Kidney Int 1999;55:907-16. (Pubitemid 29100702)
40. Huijberts MS, Schaper NC, Schalkwijk CG. Advanced glycation end products and diabetic foot disease. Diabetes Metab Res Rev 2008;24:S19-24.
41. Bocci V. Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res 2006;37:425-35.
42. Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharmacol 2006;216:493-504. (Pubitemid 44584318)
43. Bocci V. The case for oxygen-ozonetherapy. Br J Biomed Sci 2007;64:44-9. (Pubitemid 46952972)
44. Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev 2009;29:646-82.
45. Vanderlinde ES, Heal JM, Blumberg N. Autologous transfusion. BMJ 2002;324:772-5. (Pubitemid 34274264)
46. Travagli V, Zanardi I, Silvietti A, Bocci V. A physicochemical investigation on the effects of ozone on blood. Int J Biol Macromol 2007;41:504-11. (Pubitemid 47575746)
47. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000;279:L1005-28.
48. Hernandez F, Menendez S, Wong R. Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radic Biol Med 1995;19:115-9.
49. León OS, Menéndez S, Merino N, Castillo R, Sam S, Pérez L, et al. Ozone oxidative preconditioning: a protection against cellular damage by free radicals. Mediators Inflamm 1998;7:289-94. (Pubitemid 28419524)
50. Calabrese EJ. Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp Toxicol 2010;29:249-61.
51. Bocci V, Aldinucci C, Mosci F, Carraro F, Valacchi G. Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm 2007;26785. doi: 10.1155/2007/26785.
52. Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, et al. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 2001;7:693-8. (Pubitemid 32588025)
53. Morita T, Kourembanas S. Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide. J Clin Invest 1995;96:2676-82.
54. Jia L, Bonaventura C, Bonaventura J, Stamler JS. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996;380:221-6. (Pubitemid 26090643)
55. Rassaf T, Preik M, Kleinbongard P, Lauer T, Heiss C, Strauer BE, et al. Evidence for in vivo transport of bioactive nitric oxide in human plasma. J Clin Invest 2002;109:1241-8. (Pubitemid 34496602)
56. Valacchi G, Bocci V. Studies on the biological effects of ozone: 11. Release of factors from human endothelial cells. Mediators Inflamm 2000;9:271-6.
57. Al-Dalain SM,Martinez G, Candelario-Jalil E, Menendez S, Re L, Giuliani A, et al. Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats. Pharmacol Res 2001;44:391-6. (Pubitemid 33105079)
58. Martínez G, Al-Dalain SM, Menéndez S, Giuliani A, León OS. Ozone treatment reduces blood oxidative stress and pancreas damage in streptozotocin induced diabetes model in rats. Acta Farmacéutica Bonaerense 2005;24:491-7.
59. Bocci V, Borrelli E, Corradeschi F, Valacchi G. Systemic effects after colorectal insufflation of oxygen-ozone in rabbits. Int J Med Biol Environ 2000;28:109-13. (Pubitemid 32737398)
60. Barakat SAE, Saleh NKM, Thabet SS, Saleh HA, Fayez MA. effect of medical ozone therapy on diabetes-induced cardiac dysfunction. J Arab Soc Med Res 2008;3:167-75.
61. Martínez-Sánchez G, Al-Dalain SM, Menéndez S, Re L, Giuliani A, Candelario-Jalil E, et al. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol 2005;523:151-61. (Pubitemid 41562387)
62. Bocci V. The actual therapeutic modalities. In: Bocci V, editor. Ozone. A new medical drug. Dordrecht, The Netherlands: Springer; 2005. p. 37-73.
63. Bocci V, Zanardi I, Michaeli D, Travagli V. Mechanisms of action and chemical-biological interactions between ozone and body compartments: a critical appraisal of the different administration routes. Curr Drug Ther 2009;4:159-73.
64. Eliakim R, Karmeli F, Rachmilewitz D. Ozone enema: a model of microscopic colitis in rats. Dig Dis Sci 2001;46:2515-20. (Pubitemid 33042360)
65. Jacobs MT. Untersuchung über Zwischenfalle und typische Komplikationen in der Ozon-Sauerstoff-Therapie. OzoNachrichten 1982;1:5-11.
66. Travagli V, Zanardi I, Bocci V. Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims. Recent Pat Antiinfect Drug Discov 2009;4:130-42.
67. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007;50:18-25. (Pubitemid 46035847)
68. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatments of diabetic foot ulcers. British J Surg 2003;90:133-46. (Pubitemid 36237887)
69. Sherman RA. Maggot therapy for treating diabetic foot ulcers unresponsive to conventional therapy. Diabetes Care 2003;26:446-51. (Pubitemid 36929071)
70. Armstrong DG, Lavery LA, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005;366:1704-10.